Clinical Trials
15 trialsNCT04108195 2026-05-08
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04634552 2026-05-08
MonumenTAL-1
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT05050097 2026-05-08
MonumenTAL-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05552222 2026-05-08
MajesTEC-7
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06285318 2026-05-08
REALiTEC/TAL
Janssen-Cilag Ltd.
Recruiting
NCT06500884 2026-05-08
Talisman
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT06550895 2026-05-08
MonumenTAL-8
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT06577025 2026-05-08
aMMbition
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT05455320 2026-04-13
MonumenTAL-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT06208150 2026-03-13
MonumenTAL-6
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT03601078 2026-03-04
KarMMa-2
Celgene
Phase 2 Completed
NCT04586426 2026-01-16
RedirecTT-1
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting
NCT05503550 2025-12-16
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
No longer available
NCT05757973 2025-12-09
Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Approved for marketing
NCT04773522 2025-10-01
A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Janssen Pharmaceutical K.K.
Phase 1 Completed